Mandate

Vinge has advised Oncopeptides in connection with its rights issue

March 14, 2024

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with issue proceeds of approximately SEK 300 million before deduction of transaction costs.

Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Vinge’s team consisted of Dain Hård Nevonen, William Kåge, Joel Magnusson, Annie Fällström and Maximilian Bengtsson.

Related

Vinge advises Revivo Group on the acquisition of IdeaPaint

Revivo Group is continuing its expansion in Finland through the acquisition of IdeaPaint Oy, a Tampere-based company specialising in industrial surface treatment.
September 21, 2026

Vinge advises Fortinova Fastigheter AB (publ) on its first SEK 200 million green bond issue

Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) on the company’s first issue of senior unsecured green bonds in an aggregate principal amount of SEK 200 million, under a framework of up to SEK 600 million. Nordea, acted as sole bookrunner in connection with the bond issue.
September 18, 2026

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026